Financials data is unavailable for this security.
View more
Year on year Chongqing Genrix Biopharmaceutical Co Ltd had net income fall 39.03% from a loss of 576.37m to a larger loss of 801.32m despite a 154.92% increase in revenues from 475.24k to 1.21m.
Gross margin | -214.22% |
---|---|
Net profit margin | -71,021.27% |
Operating margin | -71,021.02% |
Return on assets | -20.89% |
---|---|
Return on equity | -27.79% |
Return on investment | -21.71% |
More ▼
Cash flow in CNYView more
In 2023, Chongqing Genrix Biopharmaceutical Co Ltd increased its cash reserves by 5,769.30%, or 2.84bn. Cash Flow from Financing totalled 3.10bn or 255,866.66% of revenues. In addition the company used 377.58m for operations while cash from investing totalled 120.62m.
Cash flow per share | -- |
---|---|
Price/Cash flow per share | -- |
Book value per share | 6.81 |
---|---|
Tangible book value per share | 6.70 |
More ▼
Balance sheet in CNYView more
Current ratio | 20.50 |
---|---|
Quick ratio | 20.06 |
Total debt/total equity | 0.2584 |
---|---|
Total debt/total capital | 0.2053 |
More ▼